Tom Brady & Linda Yaccarino on Startup eMed, GLP-1s

Tom Brady and eMed CEO Linda Yaccarino discussed investment in health startup eMed, highlighting rising GLP-1 weight-loss drug costs and how former athletes can evaluate business opportunities. The discussion took place at the Milken Institute Global Conference in Beverly Hills. The article is primarily commentary/interview content with limited direct market-moving information.

Analysis

This is less a single-stock read-through than a signal on how GLP-1 economics are evolving from a drug-cost story into a distribution-and-adherence story. The investable second-order effect is that the highest-margin layer may migrate away from pure pharma toward the platforms that solve access, navigation, and persistence; if consumers need help with coverage, documentation, and follow-up, the value chain shifts toward digital health intermediaries and employer-facing benefits admins. That creates a winner-take-more dynamic for companies that can aggregate demand and lower churn, while small point solutions get squeezed by CAC inflation and reimbursement friction.

The near-term catalyst path is uneven: the market tends to overreact to headline demand for weight-loss drugs, but the real monetization usually shows up over 2-6 quarters through employer benefit adoption, insurer policy updates, and repeat usage curves. The risk is that sustained high drug costs provoke utilization controls, tighter prior auth, or benefit exclusions, which would cap the addressable market even if consumer interest remains strong. A second-order loser is any adjacent wellness or telehealth model that relies on discretionary spend but lacks a durable insurance reimbursement bridge.

The governance angle matters because celebrity-backed health startups often get premium valuations before proving retention economics. That premium can reverse quickly if cohort data show high dropout after the first refill cycle or if customer acquisition depends on episodic media attention rather than repeatable referral loops. The contrarian view is that the market may be underestimating how sticky this category can become once the workflow is embedded in employer benefits and physician networks; in that case, the real moat is not the drug itself, but the operating layer around it.

Key Decisions for Investors

• Long HIMS on 3-9 month horizon as the clearest public-market proxy for GLP-1 access and persistence; best risk/reward if the company can prove improving refill retention and lower payer friction. Risk: multiple compression if churn metrics disappoint.
• Long TDOC selectively on any selloff tied to 'telehealth is dead' sentiment; optionality exists if it becomes a benefits-administration layer for obesity care, but position size should be smaller because execution risk is high. Timeframe: 6-12 months.
• Short basket of discretionary wellness names with weak reimbursement exposure if GLP-1 adoption accelerates but consumer payment burden remains high; the thesis is that spend consolidates into insured channels rather than broad wellness wallets. Use as a relative-value hedge against digital-health longs.
• Consider call spreads on HIMS or a paired long HIMS / short a broader healthcare services ETF for a 2-4 quarter horizon, expressing the view that platform economics improve faster than the market expects. Exit if insurers materially tighten access rules.
• Avoid paying up for pre-revenue celebrity-led health startups until retention and payer mix are visible; if forced, wait for first meaningful commercial data readout rather than story-driven financings.